KELIX bio expands into Moroccan market by acquiring Pharmaceutical Institute

  • Pharmaceutical Institute is an established player in the Moroccan pharma market, with strong manufacturing and distribution capabilities
  • Subject to regulatory approvals, it will mark the fourth investment by KELIX bio, a first of its kind pan-African pharmaceutical platform, established by founding investors DPI, CDC and the EBRD to broaden access to life-saving drugs across continent
  • Acquisition will be financed as part of second funding round of up to $200 million into KELIX bio, led by DPI and CDC
  • Funding round will take capital invested in KELIX bio to $450 million, with plans for additional investment of $300 million over the next two years to fund further acquisitions
  • KELIX bio has a strong pipeline of potential investments, as it looks to accelerate delivery of affordable life-saving drugs across the continent

Development Partners International (DPI), a premier investment firm focused on Africa with $2.8bn in assets under management including co-investments, and CDC Group (CDC), the UK’s development finance institution that will shortly be renamed British International Investment (BII), today announced that an agreement has been signed for KELIX bio to acquire Pharmaceutical Institute (PHI), a Moroccan-headquartered producer and distributor of generic and therapeutic pharmaceuticals. The acquisition, which will be financed through up to a $200 million second round of funding into KELIX bio led by DPI and CDC/BII, is subject to regulatory approvals in Morocco. It is expected to close in the first quarter of 2022.

Founded in 1989 by the Sedrati family, PHI is a leading manufacturer and distributor of pharmaceutical products in Morocco. The company has a strong international partners network and complementary manufacturing capabilities that will support KELIX bio’s strategy to create local ecosystems for production and distribution. The proposed acquisition will mark KELIX bio’s first entry into Morocco, an important market on the continent, and gateway into the Francophone Africa pharma market, as it accelerates its expansion across the region. It will also enable PHI to expand its existing product range, benefitting from

KELIX bio’s research and development capabilities, cross-selling synergies, and economies of scale it will provide. There issignificant demand in Africa for affordable speciality drugs, accessible to underserved communities that need them the most. KELIX bio, a $750 million pan-African buy and build platform, was established in 2020 by DPI, CDC and the European Bank for Reconstruction and Development (EBRD), in response to this demand. KELIX bio has an ambitious impact-focused strategy, driven by co-founders CEO Hocine Sidi-Said, and Chief Strategy Officer, Alhadi Alwazir, to improve the quality of life for people across the continent, through the delivery of critical, life-saving drugs. Adding to the bench of experience, KELIX bio has recently appointed new Chairman, Jerome Silvestre, who brings significant expertise in the global pharmaceutical and branded generics industry.

“KELIX bio is a gamechanger that has the potential to transform the African pharmaceutical industry – a sector that has historically been significantly underserved and inaccessible to many. Signing this new agreement to acquire PHI demonstrates KELIX’s strong pipeline of opportunities and will enable it to continue to create significant long-term impact for communities across Africa, through delivery of essential and life-saving drugs. As a founding investor in KELIX bio, we look forward to continuing our partnership with the management team, BII, EBRD and future investors to the platform, as it progresses with its expansion.”

Sofiane Lahmar, Partner at DPI commented,

“BII is helping to build productive, sustainable and inclusive economies for the benefit of those that need our capital the most. Providing access to affordable drug treatments is a vital part of that mandate.”

Nick O’Donohoe, Chief Executive at CDC/BII, said:

Since its creation in 2020, KELIX bio has already seen rapid growth, demonstrated by its annual sales growing by 44% in 2021. The acquisition of PHI will be the fourth in two years, reaffirming KELIX’s commitment to Africa. The latest funding round by DPI and CDC will bring total capital invested to $450 million, which will be supported by an additional $300 million of planned investment over the next two years, as KELIX bio looks to fund its strong pipeline of opportunities, establish new cross-market distribution channels and support research and development of new drugs.

 “We are pleased to have reached an agreement with Pharmaceutical Institute to join Kelix Bio, as we focus on our mission of improving access to affordable specialty drugs across Africa. PHI is a leader in the Moroccan pharmaceutical sector, with excellent manufacturing capabilities and a strong distribution network. We are confident, that subject to regulatory approvals, they will be a great addition to KELIX bio and also look forward to continuing partnership with DPI, CDC and EBRD.”

Jerome Silvestre, KELIX bio Chairman, said:

Kelix bio used Sijilmasa Ltd (Mr Amine Rezzouk) as financial advisor and Naciri & Associés Allen & Overy as legal advisor. UGGC was legal advisor to the Sedrati family.

CDC Group

Nichole Manhire

Is the media and brand manager at GFA News. She works very closely with editors and podcasters that contribute to telling the African business success story. For marketing and advertising send Nichole an email:

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button